Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - H.C. Wainwright raised its price target on Harrow Health (NASDAQ:HROW) to $64.00 from $60.00 on Wednesday, while maintaining a Buy rating following the company’s second-quarter financial results. According to InvestingPro data, analyst targets for the stock range from $42 to $65, with a strong consensus recommendation of 1.14 (Strong Buy). The company currently appears undervalued based on InvestingPro’s Fair Value analysis.
Harrow Health reported total revenue of $63.7 million for the second quarter of 2025, representing 30% year-over-year growth, though falling short of H.C. Wainwright’s projection of $68.0 million. The company posted net income of $5.0 million, or $0.13 per diluted share, exceeding the firm’s estimated income of $1.1 million. InvestingPro data shows impressive last twelve months revenue growth of 47.69% and a healthy gross margin of 74.56%. Get access to 12 additional ProTips and comprehensive financial metrics with InvestingPro.
VEVYE, Harrow’s dry eye treatment, showed 66% sequential prescription volume growth in the second quarter to 119,526, including approximately 50,000 new prescriptions. The product gained 2.6% market share during the quarter to reach a total dry eye disease market share of 7.8%, surpassing CEQUA to become the second-largest cyclosporine-based dry eye brand being prescribed in the U.S.
Despite strong prescription growth, VEVYE revenue decreased to $18.6 million in the second quarter from $21.5 million in the first quarter, as the VEVYE Access for All program impacted average selling price. Harrow has expanded its pharmacy network to include a nationwide retail network, which management expects will stabilize pricing.
Harrow Health reiterated its 2025 revenue target of over $280 million, including VEVYE sales of approximately $100 million, with management expecting VEVYE to continue as the company’s leading product in coming quarters, followed by IHEEZO and TRIESENCE. InvestingPro analysis indicates a "GOOD" overall Financial Health score, with analysts expecting the company to be profitable this year. Access the detailed Pro Research Report covering Harrow Health, one of 1,400+ US stocks with comprehensive analysis available on InvestingPro.
In other recent news, Harrow Health Inc. reported its Q2 2025 earnings, surpassing analysts’ expectations with an impressive earnings per share (EPS) of $0.24, compared to the forecasted $0.01. The company’s revenue amounted to $63.7 million, marking a 30% increase from the previous year, although it fell short of the anticipated $66 million. These developments reflect the company’s strategic initiatives and product growth, which have contributed to its strong performance. Despite the revenue shortfall, the results have been met with investor optimism. Analyst firms have taken note of these earnings, highlighting the significance of Harrow Health’s ability to exceed EPS expectations. The company’s recent performance underscores its ongoing efforts to enhance its market position. Investors are closely watching Harrow Health’s strategic moves and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.